TABLE 1.
Patient Characteristics
| Characteristic | Data |
|---|---|
| Age (y) | 63.3 (30.6–84.2) |
| Sex | |
| Male | 27 (60.0%) |
| Female | 18 (40.0%) |
| MGMT promoter methylation status | |
| Methylated | 12 (26.7%) |
| Unmethylated | 33 (73.3%) |
| TERT promoter mutation status | |
| Mutant | 39 (86.7%) |
| C250T mutation | 15 (53.3%) |
| C228T mutation | 24 (33.3%) |
| Wild-type | 6 (13.3%) |
| KPS | 80% (60–100%) |
| Mode of radiotherapy | |
| Conventional | 23 (51.1%) |
| Hypofractionated | 22 (48.9%) |
| Mode of surgery | |
| Stereotactic biopsy | 35 (77.8%) |
| Microsurgical resection | 10 (22.2%) |
| Contrast enhancement | |
| Yes | 40 (88.9%) |
| No | 5 (11.1%) |
| CE-T1w MRI volume (mL) | 11.1 (0.0–112.6) |
| T2w MRI volume (mL) | 40.9 (0.0–272.0) |
| TSPO polymorphism genotype | |
| LAB | 6 (13.3%) |
| MAB | 15 (33.3%) |
| HAB | 18 (40.0%) |
| Not specified | 6 (13.3%) |
| SUVmax | 2.2 (1.0–4.7) |
MGMT = O6-alkylguanine DNA methyltransferase gene; TERT = telomerase reverse transcriptase gene; KPS = Karnofsky performance status scale; CE-T1w = contrast-enhanced T1-weighted; T2w = T2-weighted.
Qualitative data are number and percentage; continuous data are median and range.